Table 5 Distribution of factors associated with anaemia among study participants
| Â | Frequency | Multivariate analysis | ||
|---|---|---|---|---|
| Â | Anaemic group (n=176) | Non anaemic group (n=176) | aOR (95%CI) | p value |
Variables | Â | Â | Â | Â |
Gender | Â | Â | Â | Â |
Female | 69 (39.43%) | 83 (47.16%) | Reference | Â |
Male | 106 (60.57) | 93 (52.84%) | 1.37 [0.82-2.31] | 0.22 |
Age group | Â | Â | Â | Â |
1year | 57 (32.76%) | 8 (4.55%) | Reference | Â |
[2–4 years] | 89 (51.15%) | 73 (45.48%) | 0.13 [0.05-0.31] | 0.001 |
[5 – 10 years] | 28 (16.09%) | 95 (53.98) | 0.03 [0.01-0.08] | 0.001 |
Access to IPTc drug (SP-AQ) | Â | Â | Â | Â |
No | 87 (49.71%) | 88 (50%) | Reference | Â |
Yes | 88 (50.29%) | 88 (50%) | 0.78 [0.45-1.33] | Â |
Stunting | Â | Â | Â | Â |
No | 84 (48%) | 131 (74%) | Reference | Â |
Yes | 91 (52%) | 45 (25.57%) | 3.37 [1.93-5.88] | 0.001 |
Malaria Parasitaemia | Â | Â | Â | Â |
No | 166 (94.86%) | 174 (98.86%) | Reference | Â |
Yes | 9 (5.14%) | 2 (1.14%) | 5.23 [1.1-28.48] | 0.04 |
Sickle cell disorders | Â | Â | Â | Â |
No | 145 (82.86%) | 161 (91.48%) | Reference | Â |
Yes | 30 (17.14%) | 15 (8.52%) | 2.89 [1.32-6.34] | 0.008 |
Alpha Thalassemia | Â | Â | Â | Â |
No | 128 (73.14%9 | 146 (82.95%) | Reference | Â |
Yes | 47 (28.86%) | 30 (17.05%) | 1.82 [1.2-3.35] | 0.04 |